The challenges in turning epigenetic hope into clinical utility

Biotech and pharmaceutical companies are investing heavily in next-generation epigenetic programmes, but there are a number of barriers to break through before the promise of these new therapeutic approaches becomes a reality.  This presentation will cover the issues around epigenetic target selection, therapeutic areas, medicinal chemistry and toxicology and speculate on where the first successes are likely to be found.

Nessa Carey, Pfizer